1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells
    Meeting Abstract

    Santomasso, B.; Park, J. H.; Riviere, I.; Mead, E.; Halton, E.; Diamonte, C.; Purdon, T.; Senechal, B.; Li, D.; Sadelain, M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
    Meeting Abstract

    Ruppert, A. S.; Byrd, J. C.; Heerema, N. A.; Smith, M. R.; Godwin, J. E.; Couban, S.; Fehniger, T. A.; Thirman, M.; Halvorson, A. E.; Tallman, M. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Senechal, B.; Bernal, Y.; Halton, E.; Diamonte, C.; Wang, Y.; Brentjens, R. J.; Sadelain, M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Mead, E.; Santomasso, B.; Halton, E.; Diamonte, C.; Bernal, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Santomasso, B.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T.; Wang, Y.; Halton, E.; Diamonte, C.; Li, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • What are the health care costs for chronic lymphocytic leukemia?
    Meeting Abstract

    Matasar, M. J.; Byfield, S. D.; Blauer-Peterson, C.; Montez, M.; Reyes, C.; Masaquel, A.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC)
    Meeting Abstract

    McKay, R. R.; Werner, L.; Jones, A.; Choudhury, A. D.; Pomerantz, M.; Sweeney, C.; Bubley, G. J.; Slovin, S. F.; Morris, M. J.; Kantoff, P. W.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1 (c259)t in HLA-A2(+) patients with synovial sarcoma (NCT01343043)
    Meeting Abstract

    Mackall, C.; Tap, W. D.; Glod, J.; Druta, M.; Chow, W. A.; Araujo, D. M.; Grupp, S. A.; Van Tine, B. A.; Chagin, K.; Van Winkle, E.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma
    Meeting Abstract

    Konner, J. A.; Boucicaut, N. N.; O'Cearbhaill, R. E.; Zamarin, D.; Makker, V.; Sabbatini, P.; Tew, W. P.; Cadoo, K. A.; Grisham, R. N.; Aghajanian, C.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Correlation of benefit from immune checkpoint inhibitors with next gen sequencing (NGS) profiles in esophagogastric cancer (EGC) patients
    Meeting Abstract

    Ku, G. Y.; Sanchez-Vega, F.; Chatila, W.; Margolis, M.; Fein, C.; Ilson, D. H.; Hechtman, J. F.; Tuvy, Y.; Bouvier, N.; Kundra, R.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save